Aster DM Healthcare Gets HSBC Buy Rating with ₹785 Target on Strong Q4 Results
HSBC has assigned a Buy rating on Aster DM Healthcare with a target price of ₹785, citing strong Q4 results driven by improved case mix, retention of key clinical talent, and expansion in Bengaluru. The company reported a 77% rise in consolidated net profit and 18% revenue growth, while the Aster-QCIL merger with 96.68% shareholder approval is expected to close in Q1FY27.
*this image is generated using AI for illustrative purposes only.
Aster DM Healthcare has received a Buy rating from HSBC with a target price of ₹785, as the brokerage highlighted the company's strong Q4 performance driven by an improved case mix. HSBC noted further case mix upside ahead, supported by the retention of key clinical talent and strategic expansion in markets like Bengaluru, along with the anticipated completion of the Aster-QCIL merger in Q1FY27.
Q4 Consolidated Financial Performance
The company delivered strong consolidated financial results for Q4, demonstrating significant growth across key performance metrics. The consolidated performance reflects the combined strength of the healthcare network.
| Financial Metric: | Q4 Current | Q4 Previous | Growth (%) |
|---|---|---|---|
| Consolidated Net Profit: | ₹1.40 billion | ₹790.20 million | +77% |
| Consolidated Revenue: | ₹11.80 billion | ₹10.00 billion | +18% |
| Consolidated EBITDA: | ₹2.30 billion | ₹1.92 billion | +20% |
| EBITDA Margin: | 19.65% | 19.20% | +45 bps |
Combined Entity Performance Highlights
The combined proforma entity (Aster + QCIL) delivered robust financial performance for Q4FY26, showcasing significant growth across key operational metrics.
| Performance Metric: | Q4FY26 | Q4FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations: | ₹2,361 crores | ₹2,002 crores | +18% |
| Operating EBITDA: | ₹517 crores | ₹414 crores | +25% |
| Operating EBITDA Margin: | 21.90% | 20.70% | +120 bps |
| Total Patient Volumes: | 1.93 million | - | +12% YoY |
| Occupancy Rate: | 61% | - | +210 bps |
Merger Implementation Progress
The proposed merger between Aster DM Healthcare and QCIL has received overwhelming shareholder approval, with 96.68% of total votes cast in favor of the transaction. The merger is expected to be completed in Q1FY27, creating one of India's largest hospital networks. The company added 373 beds during the year, bringing total bed capacity to 10,623 beds as of March 31, 2026. The expansion strategy focuses on both brownfield and greenfield projects, with 56% of beds planned in existing facilities and 44% in new facilities.
| Merger Details: | Status |
|---|---|
| Shareholder Approval: | 96.68% votes in favor |
| Expected Completion: | Q1 FY27 |
| Combined Bed Capacity: | 10,623 beds |
| Pipeline Expansion: | 4,445 additional beds planned |
Earnings Call Recording Details
The company has made the earnings call recording accessible to investors and stakeholders through its official website. The recording covers discussions on financial results for the quarter and year ended March 31, 2026.
| Recording Details: | Information |
|---|---|
| Call Date: | May 1, 2026 |
| Website Location: | asterdmhealthcare.in/investors/financial-information/audio-video-recordings-earnings-quarterly-calls |
| Regulatory Compliance: | SEBI Regulation 30 |
| Company Secretary: | Hemish Purushottam |
Historical Stock Returns for Aster DM Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.73% | +3.19% | +11.74% | +14.12% | +31.04% | +411.45% |
How will the Aster-QCIL merger completion in Q1FY27 impact the combined entity's ability to negotiate better pricing with insurers and attract institutional patients?
With 4,445 additional beds in the pipeline, what financing strategy is Aster DM Healthcare likely to pursue, and how might this affect its debt-to-equity ratio over the next 2-3 years?
Given the strategic expansion focus on Bengaluru, which other Tier-1 or Tier-2 markets could Aster DM Healthcare target next to diversify its geographic revenue concentration?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
